CARDIFF ONCOLOGY, INC. Deferred Rent Credit, Noncurrent
CARDIFF ONCOLOGY, INC. (CRDF) had Deferred Rent Credit, Noncurrent of $0 as of 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredRentCreditNoncurrent · last filed 2020-02-27
- 2019-12-31: Deferred Rent Credit, Noncurrent $0.00.
- 2019-09-30: Deferred Rent Credit, Noncurrent $0.00.
- 2019-06-30: Deferred Rent Credit, Noncurrent $0.00.
- 2019-03-31: Deferred Rent Credit, Noncurrent $0.00.
| Period end | Deferred Rent Credit, Noncurrent |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-27 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-07 |
| 2018-12-31 | $1.09M 10-K · filed 2020-02-27 |
| 2018-09-30 | $1.20M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $1.00M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $1.10M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $1.18M 10-K · filed 2019-03-06 |
| 2017-09-30 | $1.15M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $1.24M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $1.31M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $1.37M 10-K · filed 2018-02-26 |
| 2016-09-30 | $1.45M 10-Q · filed 2016-11-09 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |